Latest

The day's market news, with the argument attached

New notes every trading day on earnings, policy and market structure. Each one opens with the conclusion, then the evidence, then the companies it hits.

What Big Funds Own22 fundsWhat Berkshire, Bridgewater and other big funds reported holding last quarter.What Analysts Expect16 stocksRatings and price targets from the big institutions, each with its public source.

2026-08-26

NVDA’s Aug. 26 guide-bar signals the market is paying for custom silicon, not just hyperscaler capex insight cover

Markets / Event

Aug 26, 2026

7 min read

NVDA’s Aug. 26 guide-bar signals the market is paying for custom silicon, not just hyperscaler capex

NVIDIA’s Aug. 26 outlook framed AI buildout as a compute “mix” story: more spend is expected to land in architectures customers design around rather than only NVIDIA’s standard rack-scale GPUs. That shift reframes near-term winners across the ASIC/custom-silicon supply chain and the “neo-cloud” operators that monetize scarce compute first—while leaving hyperscaler-heavy capex bets more exposed to timing risk.

NVIDIA revenue run-rate: $253.5BNVIDIA net income run-rate: $159.6B

Apollo’s “China Shock 2.0” isn’t about cheap goods—it’s about a deflation-export regime that can keep US margins under pressure even as the Fed leans toward disinflation

Apollo’s chief economist frames “China Shock 2.0” as China accelerating advanced manufacturing exports on the back of overcapacity, turning global disinflation into an industry-by-industry margin problem. The key investor question is which US businesses absorb the next tariff-proof squeeze first—durable autos, solar and residential electrification supply chains, and steel-intensive industrials—while September Fed pricing responds to lower inflation prints rather than stabilizing corporate profit pools.

Tesla profitability level: Lower returns in FY2025 vs FY202Ford Motor valuation sensitivity: Lower enterprise-value efficienc

Boston Scientific's cyberattack hits order/shipping systems—so medtech investors should price a new “working-capital + revenue-timing” risk

Boston Scientific BSX disclosed a global cyberattack that disrupted operations and is expected to continue limiting access to systems that support “the ability to process and ship customer orders.” The immediate market question isn’t just whether product manufacturing stopped—it’s whether order intake and fulfillment delays push revenue recognition into later quarters and increase working-capital and charge risk at the same time BSX is running a large restructuring program.

Q2 FY2026 revenue: $5.44BQ2 FY2026 net income: $907M

New Nasdaq ETF TGRZ lets US investors bet on China LLMs—without fixing the core decoupling math

When TGRZ begins trading on Nasdaq, it packages exposure to China’s large-language-model ecosystem into a single listed wrapper. The opportunity is real, but investors should model two frictions at once: export-control gating that can cap addressable demand, and single-country, single-theme concentration that makes valuation and liquidity risks hit the whole basket together.

Event Date: 2026-08-26Topic Type: Markets / Event

CrowdStrike +11% and Okta +19% aren’t just beats: they confirm AI-driven breaches are turning into measurable security and identity spend

CrowdStrike’s Q2 showed record momentum around Falcon Flex (ending ARR from Flex adopters exceeding $2.29B) while Okta’s Q2 delivered $728M revenue (+13% YoY) with raised FY2026 guidance. Taken together, they support a new “AI threat → paid security outcomes” demand line—reshaping how investors should think about identity pricing power and reducing the odds that Microsoft bundling alone will cap standalone security growth.

CrowdStrike (Q2 FY2027): $1.47BCrowdStrike (net new ARR): $333M

Deloitte’s $21.5M DEI settlement turns federal contractors’ “policy risk” into a budget line—and sets a probe-first enforcement template

Deloitte agreed to pay $21.5M to resolve U.S. Department of Justice allegations tied to anti-discrimination certification terms in federal contracts, effectively translating DEI-related compliance into quantifiable settlement exposure. For government-services contractors, the key shift is less about headlines and more about how FCA-style probes can reframe personnel programs as contractual falsity, raising both controls spending and bid-to-bid variance in compliance costs.

Settlement value: $21.5MCovered contract period (alleged): 2017–present

Akzo Nobel’s Dulux owner rejects a £14.5B break-up bid—what that implies for the next price investors should underwrite for global coatings assets

Akzo Nobel rejected a €12.5B all-cash bid from Nippon Paint and Sherwin-Williams tied to splitting the group, arguing the proposal lacked certainty and did not qualify as a “Superior Proposal.” That rejection effectively sets a higher valuation floor for whole-company consolidation of coatings capacity—while also clarifying where “DIY-slow” cycle risk is being priced into deal math for the next would-be buyer.

Indicated cash offer price: €73.00/shareTotal offer value: €12.5B

FDA clears the first continuous dual glucose–ketone wearable—turning CGM into the metabolic control panel the GLP-1 era never had

On Aug 25, 2026, the FDA authorized Abbott’s Libre Duo 10 Day as the first wearable in the U.S. to continuously monitor both ketones and glucose in a single device, primarily to provide earlier warning of rising ketones that can precede diabetic ketoacidosis. The upgrade matters for investors because it expands the measurement layer of metabolic health beyond diabetes, and it forces a new competitive map for CGM-like “sensor + app + alerts + integrations” platforms across the obesity/GLP-1 value chain.

Clinical program size: 600+ participantsBackground monitoring claim: Every minute

Generate Biomedicines’ lock-up expiry isn’t “just” an overhang—it’s a test of how scarce investors view AI-native protein design

Generate Biomedicines’ post-IPO lock-up is set to end roughly 180 days after its Feb. 27, 2026 public trading start, setting up a predictable supply overhang. The stock’s rally into the date implies investors believe AI-native protein design (and the company’s drug-development execution) can absorb the added float risk faster than dilution anxiety can spread.

Revenue base: $31.9MR&D intensity: R&D $224.7M

Gunvor’s >$1B Haynesville bid flags a gas-trading power shift: feedgas control is the scarce margin

Gunvor is reportedly in talks to buy Haynesville shale assets for more than $1B, a sign that LNG-era economics are pulling trading-house capital into US gas basins. The deal’s implied wager is that the export margin increasingly depends on securing feedgas access (and bottleneck capacity) rather than simply owning more production barrels of hydrocarbons.

Reported consideration range: $1.2B–$1.5BNet acreage: 58,000 acres (approx.)

Haidilao’s delivery-and-multi-brand pivot turns margin defense into a discretionary-spending tell

In its latest interim update filed with Hong Kong exchange, Haidilao International Holding reported delivery revenue surging to RMB 2,051.4 million (+121.2%) and “other restaurant operations” rising to RMB 1,271.4 million (+113.1%). The implication for investors is sharper than the headline: if delivery mix plus multi-brand scale are holding steady profitability while same-store sales flatten, China consumers may be shifting spend back toward value-focused occasions rather than trading down to silence.

Delivery business revenue: RMB 2,051.4mDelivery revenue share of group: 9.2%

HEICO proves aerospace aftermarket is where profits accumulate (Q3 FY2026 net income +33%)

In HEICO’s third quarter of fiscal 2026, record sales and net income rose 33% to a record $235.4M, outperforming the OEM build-rate narrative. The quarter reinforces why aerospace aftermarket—replacement parts supply and repair/overhaul—can monetize fleet utilization even when OEM delivery timelines slip.

Third quarter fiscal 2026 net income: $235.4MThird quarter fiscal 2026 net sales: $1.413B

HP licensing Huawei Wi‑Fi patents doesn’t “break the firewall” — it exposes the real gray zone: standards-essential IP vs. export-control intent

HP’s reported multi-year, global Wi‑Fi patent licensing deal with Huawei highlights how US-China decoupling can stop at device supply while still allowing cross-border access to standards-essential intellectual property. For connectivity-silicon investors, the actionable takeaway is that Wi‑Fi royalties and licensing pools—not just chip sourcing—can keep Huawei-linked IP flowing even under stricter trade rules.

HP revenue (TTM): $57.4BOperating cash flow (TTM): $4.6B

India’s special NRI deposit window is importing “hot” global dollars—and the winners are the banks that monetize it

A targeted RBI window for foreign-currency NRI deposits reportedly pulled in $73B in 11 weeks, with incentives set to end Aug. 31. The direct beneficiary is India’s banking deposit-gathering machine: inflows can lower funding stress and support rupee stability, while banks with the strongest NRI franchises are positioned to convert that funding into earnings—until rollover risk rises if global rates move or incentives expire.

Revenue (TTM): $4.96T INRNet interest income (TTM): $1.66T INR

Intuit's fiscal 2027 guide signals the AI bet has moved from features to payback timing

Intuit guided fiscal 2027 with mid-single-digit consumer growth but high-teens non-GAAP EPS growth, and it anchored the plan in an “AI-driven expert platform” narrative. The market question isn’t whether Intuit can add AI—it's whether AI shifts when SMB customers convert into monetizable usage, because that timing is what keeps the whole SMB software group funded.

Fiscal 2027 total revenue (GAAP): $23.28B–$23.51BFiscal 2027 GAAP diluted EPS: $20.12–$20.36

WTI under $80 flips the trade: an Iran–Oman Hormuz framework plus a U.S. sanctions ‘hold’ turns the summer’s geopolitical hedge into an oversupply bet

A reported Aug. 26 framework between Iran and Oman aims to set up a temporary navigational corridor and mine-clearing pathway for the Strait of Hormuz, while the U.S. reportedly held off on extending major secondary sanctions. That combination repriced oil from a geopolitics premium toward a reopening/flow-normalization scenario—exactly the pathway the IEA frames as moving the market from risk scarcity to oversupply-driven price pressure.

Upstream crude price driver: $4.65BEnergy Products derivative timing: $2.56B

Jazz’s Ziihera approval is the HER2 biliary-tract moment—now the investor question is how much profit Merus monetizes and how fast Jazz can move beyond a “niche” BTC label

The FDA’s Aug. 25, 2026 approval of [Ziihera (zanidatamab-hrii)] for HER2+ first-line gastroesophageal adenocarcinoma (plus the previously approved HER2+ biliary tract cancer label) ends the “yes/no” binary—turning the market focus to launch pace and unit economics. The co-development terms mean a meaningful share of incremental value flows back to Merus’ partner structure via Zymeworks milestone/royalty economics, so the profit split—not just clinical uptake—will decide whether this becomes a durable earnings lever for Jazz Pharmaceuticals rather than a headline-only win.

Ziihera product sales: $15.4MTotal revenues (company-wide): $1.208B

Marvell's Q2 FY27 print turns “custom-silicon backlog” into earnings power—or exposes it as optics

Marvell’s Q2 FY27 setup is being judged on whether it converts AI networking “bookings” into sustainable revenue, margin, and cash generation. The only defensible way to tell is to read the print alongside its outlook math: Q2 FY27 revenue guidance centers on $2.7B with a GAAP gross margin range of 52.1%–53.1% and explicit calls for “exceptional AI-related bookings.”

Q2 FY27 net revenue guidance: $2.7BQ2 FY27 GAAP gross margin: 52.1%–53.1%

Meta's $16.68B settlement turns social-media addiction litigation into a measurable EPS charge—and forces reserve math to move from “tail risk” to “run-rate”

Meta has agreed to a multi-state settlement with California and other states with a maximum payment of $16.68B under a scheduled installment structure. The agreement doesn’t just cap exposure—it prescribes teen-specific product and UI changes that create a compliance cost baseline, making future penalties/settlements for the broader platform cohort easier to model.

Settlement cap (maximum state payment): $16.68BPrimary instrument: Consent judgment exhibits

Mortgage Demand Slips Again as the Fed’s September “Hike-or-Cut” Window Peaks

Mortgage demand is showing the fastest, most mechanical downside to a whipsaw rate path: the MBA purchase index fell 4% and contract rates rose to 6.81% for the week ending July 31. As the Fed heads into its mid-September decision window, the real question for housing-linked earnings is whether builders can keep incentives absorbing affordability pressure— or whether demand breaks first.

30-year fixed mortgage rate: 6.81%Composite mortgage application index: -2.9%

Read article

What to expect

Evidence-first notes with a visible point of view.

This section collects sharp takes on earnings, shareholder meetings, and market structure. Each new piece should make the thesis, the facts, and the implications obvious within the first few screens.

Expect direct analysis, not generic commentary.

Expect the data to be explicit and the argument to be easy to follow.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer